Failure of ELM-PC 5: An ineffective drug or an unfit end point?

Journal of Clinical Oncology

Volumn 33, Issue 7, 2015, Pages 679-681

  Morris, Michael J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; ORTERONEL; PLACEBO; PREDNISONE; SIPULEUCEL T; ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; COMPASSIONATE USE; CONSTIPATION; DIARRHEA; DRUG APPROVAL; DRUG MECHANISM; DRUG TREATMENT FAILURE; EDITORIAL; FEASIBILITY STUDY; HUMAN; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERSONAL EXPERIENCE; PHASE 3 CLINICAL TRIAL (TOPIC); PREMATURITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY OF LIFE; TREATMENT DURATION; VALIDATION STUDY; VOMITING; BLOOD; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR MARKERS, BIOLOGICAL;

EID: 84925337655     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.4309     Document Type: Editorial

References (18)

1. Fizazi K, Jones R, Oudard S, et al: Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol 33:723-731, 2015
2. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004
3. Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004
4. Scher HI, Fizazi K, Saad F, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187-1197, 2012
5. Ryan CJ, Smith MR, de Bono JS, et al: Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138-148, 2013
6. Parker C, Nilsson S, Heinrich D, et al: Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213-223, 2013
7. Kantoff PW, Higano CS, Shore ND, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422, 2010
8. de Bono JS, Oudard S, Ozguroglu M, et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376:1147-1154, 2010
9. de Bono JS, Logothetis CJ, Molina A, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005, 2011
10. Beer TM, Armstrong AJ, Rathkopf DE, et al: Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424-433, 2014
11. Ryan CJ, Smith MR, Fizazi K, et al: Final overall survival (OS) analysis of COU-AA-302, a randomized phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy. Presented at the European Society of Medical Oncology Congress, Madrid, Spain, September 26-30, 2014
12. De Wit R, Fizazi K, Jinga V, et al: Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapynaïve metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial). J Clin Oncol 32, 2014 (suppl 15s; abstr 5008)
13. Scher HI, Halabi S, Tannock I, et al: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-1159, 2008
14. Morris MJ, Farrelly JS, Fox JJ, et al: The Prostate Cancer Clinical Trials Consortium (PCCTC) bone scan data capture tool for clinical trials using Prostate Cancer Working Group 2 (PCWG2) criteria: Effect on data accuracy and workload. J Clin Oncol 29, 2011 (suppl; abstr 121)
15. Morris MJ, Molina A, Small EJ, et al: Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. J Clin Oncol [epub ahead of print on January 26, 2015]
16. Kluetz PG, Ning YM, Maher VE, et al: Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res 19:6650-6656, 2013
17. Morris MJ, Loriot Y, Beer TM, et al: Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo. J Clin Oncol 32, 2014 (suppl 15s; abstr 5054)
18. Scher HI, Heller G, Molina A, et al: Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. J Clin Oncol 29, 2011 (suppl; abstr LBA4517A)